We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Surface Oncology Inc (SURF) USD0.0001

Sell:$3.71 Buy:$3.85 Change: $0.21 (5.34%)
Market closed |  Prices as at close on 21 January 2022 | Switch to live prices |
Change: $0.21 (5.34%)
Market closed |  Prices as at close on 21 January 2022 | Switch to live prices |
Change: $0.21 (5.34%)
Market closed |  Prices as at close on 21 January 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Surface Oncology, Inc. is a clinical-stage, immuno-oncology company focused on developing antibody therapies focused on the tumor microenvironment. The Company is developing multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable an immunologic response and enhance outcomes for patients with cancer. Its pipeline includes two wholly owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a pre-clinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). In addition, Surface has two partnerships with pharmaceutical companies, including a collaboration with Novartis targeting CD73 (NZV930; Phase I) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813; preclinical).

Contact details

50 Hampshire St Fl 8
United States
+1 (617) 7144096

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$185.00 million
Shares in issue:
46.14 million
United States
US dollar

Key personnel

  • Denice Torres
    Chairman of the Board
  • Robert Ross
    President, Chief Executive Officer, Director
  • Jessica Fees
    Principal Financial Officer, Principal Accounting Officer, Senior Vice President, Finance, Treasurer
  • Lisa Mcgrath
    Chief People Officer
  • Vito Palombella
    Chief Scientific Officer
  • Wendy Dwyer
    Chief Business Officer
  • Alison O'Neill
    Chief Medical Officer
  • Henry Rath
    Chief Business Officer
  • Liisa Nogelo
    Chief Legal Officer, Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.